Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical ProductsLicensing Agreement • September 6th, 2021
Contract Type FiledSeptember 6th, 2021SOLANA BEACH, Calif., March 4, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY:NASDAQ) ("Imprimis") and resolutionMD LLC ("resolutionMD") have entered into a licensing agreement which will provide resolutionMD with exclusive rights to the Accudel transdermal delivery technology, for anti cellulite formulations, in the global professional skincare market.